Local Tech Wire

RESEARCH TRIANGLE PARK, N.C. – GlaxoSmithKline (NYSE: GSK) is selling a research and development facility in Croatia and has signed a new production contract for drugs in the U.K. where it continues to plan to build a new plant.

The moves, along with the also on Wednesday, are the latest in a series made by Chief Executive Officer Andrew Witty as he continues to reorganize and refocus the drug giant.

GSK is selling the R&D facility in Zagreb, Croatia, to Galapagos.

Financial terms were not disclosed. However, GSK did sign a three-year fee-for-service agreement with Galapagos worth some $20 million.

Approximately 130 GSK workers will be transferred to Galapagos.

For more details,

In the U.K., meanwhile, GSK signed a production agreement with Lonza for five early stage antibodies that are currently in Phase I and II clinical trials.

GSK also is working with Lonza in assessing options for a new biopharmaceutical manufacturing facility to be built within the U.K.

For details,

GSK maintains its U.S. headquarters in RTP.

Get the latest news alerts: at Twitter.